Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2017 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Announces Encouraging Efficacy and Safety Data from First Human Study of SM-88 in Women with Metastatic Breast Cancer

Median overall survival of 35 months in 14 progressive metastatic breast cancer patients despite multiple lines of prior therapy (average 2.5 lines of systemic drug therapy prior to SM-88)43 percent...
November 03, 2017 08:30 ET | Source: Tyme Technologies, Inc.

Tyme to Announce Second Quarter Fiscal Year 2017 Operational Update and Schedules Investor Conference Call

NEW YORK, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, announced...
October 25, 2017 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Identifies Potential Method and Biomarker for Converting Malignant Tumors to Inert Calcified Mass

Mechanism for conversion works in conjunction with SM-88’s core technologyConfirmed ability to calcify osteosarcoma tumors in canine models Identified biomarker appears to have applicability to a...
October 19, 2017 08:30 ET | Source: Tyme Technologies, Inc.

Tyme’s SM-88 Demonstrates Prolonged Overall Survival in Metastatic Cancer Patients Across Multiple Subgroups

Patients receiving no subsequent therapy experienced a longer median overall survival (OS) than patients who received subsequent treatments beyond SM-88Patients with two or more prior systemic...
September 14, 2017 08:30 ET | Source: Tyme Technologies Inc

Tyme Adds Distinguished Drug Developer, Briggs W. Morrison, M.D. to Advisory Board

NEW YORK, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today...
September 11, 2017 08:30 ET | Source: Tyme Technologies Inc

TYME Presentation at ESMO Reported 100% of Current Prostate Cancer Patients Have Demonstrated a Reduction in Circulating Tumor Cells, Most Becoming Undetectable

- Results suggest SM-88 may help avoid or delay more intensive treatments, such as chemical castration, in prostate cancer patients - - All subjects receiving study drug had radiographic progression...
September 07, 2017 09:02 ET | Source: Tyme Technologies Inc

Tyme’s Updated Long-Term Analysis Shows 29-Month Median Overall Survival in Metastatic Cancer Patients that Achieved Stable Disease

- Stable disease patient group had failed a median of two prior lines of therapy and entered the trial with progressive metastatic disease - - Analysis suggests traditional RECIST response criteria...
August 30, 2017 08:30 ET | Source: Tyme Technologies Inc

Tyme Technologies, Inc. to Present at Upcoming Investor Conferences

NEW YORK, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced that Ben...
August 29, 2017 08:31 ET | Source: Tyme Technologies Inc

Tyme Inc. to Present Prostate Cancer Data from its Ongoing Phase II Trial for SM-88 at ESMO 2017

NEW YORK, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced that it...
August 14, 2017 08:30 ET | Source: Tyme Technologies Inc

Tyme Technologies, Inc. Announces the Issuance of Two New Platform Patents

NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, announced the United...